Therapy Acceleration Program
Therapy Acceleration Program
News from 2021
TAP Partner News During ASH: Dec 2021
Current and former TAP partners presented new data during the 2021 American Society of Hematology (ASH) meeting that took place from December 11-14th.
OncoPep Completes $11 Million Series D Financing to Continue Clinical Trials and Advance Pipeline Development
CAMBRIDGE, Mass., Dec. 9, 2021 - OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D funding will enable OncoPep to continue its clinical trials and advance preclinical development of novel pipeline agents. OncoPep's lead investigational candidate, PVX-410, is a cancer vaccine in clinical development for smoldering multiple myeloma (SMM) and triple negative breast cancer (TNBC).
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
WATERTOWN, Mass., Nov. 30, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its IRAKIMiD degrader, KT-413, and is being developed initially for the treatment of relapsed/refractory MYD88-mutant DLBCL, with the potential to expand into other MYD88-mutant indications and IL-1R/NFkB-driven malignancies.
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study for CD30-positive Lymphomas
Heidelberg, Germany, November 22, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced interim clinical results from the investigator-initiated phase 1-2 study at The University of Texas MD Anderson Cancer Center, evaluating cbNK cells pre-complexed with Affimed’s innate cell engager (ICE®) AFM13. Patients treated at the recommended phase 2 dose, 100% responded after the first cycle of treatment with five CRs and seven PRs according to investigator assessment.
Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors
SAN DIEGO, Nov. 17, 2021 - Abintus Bio, Inc. (Abintus), a company pioneering first-in-class, off-the-shelf medicines that reprogram cells directly in vivo, today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products. These products have the potential to overcome the challenges of ex vivo CAR technologies and dramatically improve outcomes and access for patients with hematologic malignancies and solid tumors. Abintus’ initial funding syndicate included Takeda Ventures and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP).